Novel Drug for Relapsing-Remitting MS: New Phase 2 Data

The second-generation selective DHODH inhibitor vidofludimus calcium met a phase 2 trial primary endpoint of suppressing new active lesions on MRI and was well tolerated.

Related Keywords

Boston ,Massachusetts ,United States ,Shaheene Lakhan ,Andreas Muehler , ,Immunic Therapeutics ,Medscape Medical ,Multiple Sclerosis Ms ,Multiple Sclerosis ,Us ,Calcium ,Osteoarthritis Oa ,Steoarthritis Generalized ,A Osteoarthritis ,Egenerative Joint Disease Djd ,Rthritis Degenerative ,Eneralized Osteoarthritis ,Degenerative Arthritis ,Magnetic Resonance Imaging Mri ,Magnetic Resonance Imaging ,Ri ,Maging Magnetic Resonance ,Multiple Sclerosis Relapse ,S Relapse ,Elapse Of Multiple Scler ,